Deposition, imaging, and clearance: What remains to be done?

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue SUPPL. 2, 2010, Pages

  Scheuch, Gerhard ^a   Bennett, William ^b   Borgström, Lars ^c   Clark, Andy ^d   Dalby, Richard ^e   Dolovich, Myrna ^f   Fleming, John ^g   Gehr, Peter ^h   Gonda, Igor ⁱ   O'Callaghan, Chris ^j   Taylor, Glyn ^k   Newman, Steve ^l  

^a Activaero GmbH   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ ARADIGM CORPORATION   (United States)

^j UNIVERSITY OF LEICESTER   (United Kingdom)

^k CARDIFF UNIVERSITY   (United Kingdom)

^l Scientific Consultant   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NANOPARTICLE;

AEROSOL; ARTICLE; ASTHMA; BODY POSTURE; BRAIN; BREATHING; CHRONIC BRONCHITIS; CYSTIC FIBROSIS; DIGITAL IMAGING; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRY POWDER; ECHO PLANAR IMAGING; GAMMA SCINTIGRAPHY; HUMAN; INHALER; ISOTOPE LABELING; LUNG CLEARANCE; LUNG DEPOSIT; METERED DOSE INHALER; METHODOLOGY; MOLECULAR IMAGING; NOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASE; SCINTISCANNING; SECRETIONS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PHARMACEUTICAL PREPARATIONS; RADIONUCLIDE IMAGING; RESEARCH; TISSUE DISTRIBUTION;

EID: 78650212754     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0839     Document Type: Article

References (123)

1. Dolovich MB: Measuring total and regional lung deposition using inhaled radiotracers. J Aerosol Med. 2001;14(Suppl 1):S35-S44.
2. Chrystyn H: Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol. 2001:51: 289-299.
3. Labiris NR, and Dolovich MB: Pulmonary drug deliv-ery. Part 1: physiological factors affecting therapeutic effectiveness of aerosolised medications. Br J Clin Phar-macol. 2003;56:588-599.
4. Bennett WD: Effect of beta-adrenergic agonists on mucocili-ary clearance. J Allergy Clin Immunol. 2002;110:S291-S297.
5. Hasani A, Toms N, Agnew JE, Lloyds J, and Dilworth JP: Mucociliary clearance in COPD can be increased by both a D2/beta2 and a standard beta2 agonist. Respir Med. 2005;99:145-151.
6. Berridge MS, Lee Z, and Heald DL: Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des. 2000;6:1631-1651.
7. Smaldone GC: Radionuclide scanning, respiratory physiology and pharmacokinetics. J Aerosol Med. 2001;14:135-137.
8. Adams WP, Ahrens RC, Chen M-L, Christopher D, Chowdury BA, Connor DP, Dalby R, Fitzgerald K, Hen-deles L, Hickey AJ, Hochhaus G, Laube BL, Lucas P, Lee SL, Lyapustina S, Li B, O'Connor D, Parikh N, Parkins DA, Peri P, Pitcairn GR, Riebe M, Roy P, Shah T, Singh GJP, Suarez-Sharp S, Suman JD, Weda M, Woodcock J, Yu L: Demonstrating bioequivalence of locally acting orally in-haled drug products (OIPs): Workshop summary report, cosponsored by Product Quality Research Institute (PQRI) and Inhalation and Nasal Technology Focus Group (INTFG). J Aerosol Med Pulm Drug Deliv. 2010;23:1-29.
9. Wagner HN: Hal Anger: nuclear medicine's quiet genius. J Nucl Med. 2003;44:26N-34N.
10. Meseguer G, Gurny R, and Buri P: In vivo evaluation of dosage forms: application of gamma scintigraphy to non-enteral routes of administration. J Drug Target. 1994;2:269-288.
11. Newman SP: In vivo assessment of inhaled products. In: S Newman, P Andersen, P Byron, R Dalby, and J Peart: Re-spiratory Drug Delivery: Essential Theory and Practice. RDD Online/Virginia Commonwealth University, Richmond, VA; pp. 97-133, 2009.
12. Newman SP, Pitcairn GR, Hirst PH, and Rankin L: Radio-nuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Del Rev. 2003;55:851-867.
13. Rogers DF, and Ganderton D: Determining equivalence of inhaled medications. Respir Med. 1995;89:253-261.
14. Snell NJC, and Ganderton D: Assessing lung deposition of inhaled medications. Respir Med. 1999;93:123-133.
15. Chrystyn H: Methods to determine lung distribution of inhaled drugs\could gamma scintigraphy be the gold standard? Br J Clin Pharmacol. 2000:49:525-528.
16. Berridge MS, Heald DL, and Lee Z: Imaging studies of biodistribution and kinetics in drug development. Drug Dev Res. 2003;59:208-226.
17. Newman SP: Characteristics of radiolabelled versus un-labelled inhaler formulations. J Aerosol Med. 1996;9(Suppl 1):S37-S47.
18. Dolovich MB: In vitro measurements of delivery of medi-cations from MDIs and spacer devices. J Aerosol Med 1996;9(Suppl 1):S49-S58.
19. Macey DJ, and Marshall R: Absolute quantitation of ra-diotracer uptake in the lungs using a gamma camera. J Nucl Med. 1982;23:731-735.
20. Pitcairn GR, and Newman SP: Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med. 1997;10:187-198.
21. Fok TF, Al-Essa M, Kipalani H, Monkman S, Bowen B, Coates G, Dolovich M. Estimation of pulmonary deposition of aerosol using gamma scintigraphy. J Aerosol Med 1999; 12:9-15.
22. Everard ML, and Dolovich MB: In vivo measurement of lung dose. In: H Bisgaard, C O'Callaghan, and GC Smal-done (eds). Drug Delivery to the Lung. Marcel Dekker, New York; pp. 173-209, 2002.
23. Warren S, and Taylor G: Morphometric measures for tissue attenuation corrections in pharmaceutical scintigraphy. AAPS PharmSci. 2003;5:M1079.
24. Dolovich MB, Sanchis J, Rossman C, and Newhouse MT: Aerosol penetrance: a sensitive index of peripheral airway obstruction. J Appl Physiol. 1976;40:468-471.
25. Pitcairn G, Joyson A, Hirst P, Prior D, and Newman S: Lung penetration profiles: a new method for analyzing regional lung deposition data in scintigraphic studies. In: RN Dalby, PR Byron, J Peart, and SJ Farr (eds). Respiratory Drug Delivery VIII. Davis Horwood, Raleigh, NC; pp. 549-552, 2002.
26. Agnew JE: Characterizing lung aerosol penetration. J Aerosol Med. 1991;4:237-249.
27. Tossici-Bolt L, Fleming JS, Conway JH, and Martonen TB: Analytical technique to recover the third dimension in planar imaging of inhaled aerosols: (1) impact on spatial quantification. J Aerosol Med. 2006;19:565-579.
28. Dolovich M, Rhem R, Kish S, Saab C: Defining lung regions for the purpose of calculating deposition to the small air-ways. Am J Respir Crit Care Med. 2002;165:A190.
29. Tossici-Bolt L, Fleming JS, Conway JH, and Martonen TB: An analytical technique to recover the third dimension in planar imaging of inhaled aerosols: (2) estimation of the deposition per airway generation. J Aerosol Med. 2007; 20:127-140.
30. Fleming JS, and Conway JH: Three-dimensional imaging of aerosol deposition. J Aerosol Med. 2001;14:147-153.
31. Köhler D, Fleischer W, and Matthys H: A new method for easy labelling of beta-2 agonists in the metered dose inhaler with technetium 99m. Respiration. 1988;53:65-73.
32. Pitcairn GR, Hooper G, Luria X, Rivero X, and Newman SP: A scintigraphic study to evaluate the deposition patterns of a novel anti-asthma drug inhaled from the Cyclohaler dry powder inhaler. Adv Drug Del Rev. 1997;6:59-67.
33. Pitcairn GR, Lim J, Hollingworth A, and Newman SP: Scintigraphic assessment of drug delivery from the Ultra-haler dry powder inhaler. J Aerosol Med. 1997;10:295-306.
34. Walker PS, Conway JH, Fleming JS, Bondesson E, and Borgström L: Pulmonary clearance rate of two chemically different forms of inhaled pertechnetate. J Aerosol Med. 2001;14:209-215.
35. Eberl S, Chan H-K, and Daviskas E: SPECT imaging for radioaerosol deposition and clearance studies. J Aerosol Med. 2006;19:8-20.
36. Pitcairn G, James J, Joyson A, Hirst P, and Newman S: Technecoat: a novel method for radiolabelling dry powder formulations in radionuclide imaging studies. In: RN Dal-by, PR Byron, J Peart, and SJ Farr (eds). Respiratory Drug Delivery VIII. Davis Horwood, Raleigh, NC; pp. 553-556, 2002.
37. Perring S, Summers Q, Fleming JS, Nassim MA, and Hol-gate ST: A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium admin-istered by metered dose inhaler. Br J Radiol. 1994;67:46-53.
38. Phipps P, Gonda I, Bailey D, Borham P, Bautovich G, and Anderson S: Comparison of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis. 1989;139:1516-1523.
39. Regnis JA, Robinson M, Bailey DL, Cook P, Hooper P, Chan H-K, Gonda I, Bautovich G, and Bye PTP: Mucocili-ary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med. 1994;150:66-71.
40. Daviskas E, Anderson SD, Gonda I, Chan H-K, Cook P, and Fulton R: Changes in mucociliary clearance during and after isocapnic hyperventilation in asthmatic and healthy subjects. Eur Respir J. 1995;8:742-751.
41. Fleming JS: Measuring drug deposition by airway genera-tion in humans. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery IX. Davis Healthcare International, River Grove, IL; pp. 187-193, 2004.
42. PitcairnG, Kalirai C,Joyson A, Newman SP, and Fleming JS: Development of a standard method for quantifying regional lung deposition from SPECT and relating the data to airway anatomy. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr, (eds). Respiratory Drug Delivery IX. Davis Healthcare International, River Grove, IL; pp. 621-624, 2004.
43. Fleming JS, Sauret V, Conway JH, Holgate ST, Bailey AG, and Martonen TB: Evaluation of the accuracy and preci-sion of lung aerosol deposition measurements from SPECT using simulation. J Aerosol Med. 2000;13;187-198.
44. Weibel ER: Morphometry of the Human Lung. Academic Press, New York; 1963.
45. Fleming JS, Quint M, Bolt L, Martonen TB, and Conway JH: Comparison of SPECT aerosol deposition data with twenty-four hour clearance measurements. J Aerosol Med. 2006;19:261-267.
46. Fleming JS, Epps B, Conway JH, and Martonen TB: Com-parison of SPECT aerosol deposition data with a human respiratory tract model. J Aerosol Med. 2006;19:268-278.
47. Basu S, and Alavi A: Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008;49:17N-21N and 37N.
48. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, and Alavi A: Positron emission tomography as a diagnostic tool in infection: present role and future possi-bilities. Semin Nucl Med. 2009;39:36-51.
49. Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W. and Alavi A: Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med. 2009;9:124-145.
50. Rhodes CG, and Hughes JM: Pulmonary studies using positron emission tomography. Eur Respir J. 1995;8:1001-1017.
51. Dolovich M, Nahmias C and Coates G: Unleashing the PET: 3D imaging of the lung. In: PR Byron, R Dalby, and SJ Farr (eds). Respiratory Drug Delivery VII. Serentec Press, Raleigh, NC; pp. 215-230, 2000.
52. Lavalaye J, Grutters JC, Van De Garde EM, Van Buul MM, Van Den Bosch JM, Windhorst AD, and Verzijlbergen FJ: Imaging of fibrogenesis in patients with idiopathic pul-monary fibrosis with cis-4-[(18)F]-Fluoro-L:-proline PET. Mol Imaging Biol. 2009;11:123-127.
53. Elsinga PH: Radiopharmaceutical chemistry for positron emission tomography. Methods. 2002;27:208-217.
54. Allard M, Fouquet E, James D, and Szlosek-Pinaud M: State of art in 11C labelled radiotracers synthesis. Curr Med Chem. 2008;15:235-277.
55. Dolovich M, Rhem R, Guo H, Labiris NR, and Thabane L: Does particle size influence distribution of inhaled therapy in the presence of airways obstruction: a3D PET study of the lung in cystic fibrosis? Proc Am Thorac Soc. 2005;2:A377.
56. Ojima F, Ido T, Takahashi T, Hatazawa J, Ito M, Sasaki H, Yanai M, Aikawa T, Takishima T, Abiko K, and Amano K: Preparation of a fine powder of 2-deoxy-2-[18F]fluoro-D-glucose suitable for inhalation to diagnose lung diseases by means of PET. Ann Nucl Med. 1989;3:143-147.
57. Berridge MS, and Heald DL: In vivo characterization of inhaled pharmaceuticals using quantitative positron emis-sion tomography. J Clin Pharmacol. 1999;39:25S-29S.
58. Visser TJ, Van Waarde A, Doze P, Elsinga PH, Van Der Mark TW, Kraan J, Ensing K, and Vaalburg W: Char-acterisation of [beta]2-adrenoceptors, using the agonist [11C] formoterol and positron emission tomography. Eur J Pharmacol. 1998;361:35-41.
59. Bergstrom M, Cass LM, Valind S, Westerberg G, Lundberg EL, Gray S, Bye A, and Langstrom B: Deposition and dis-position of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission to-mography. Clin Pharmacokinet. 1999;36(Suppl 1):33-39.
60. Berridge MS, Lee Z, and Heald DL: Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. J Nucl Med. 2000;41:1603-1611.
61. Guenther KJ, Yoganathan S, Garofalo R, Kawabata T, Strack T, Labiris R, Dolovich M, Chirakal R, and Valliant JF: Synthesis and in vitro evaluation of 18F-and 19F-labeled insulin: a new radiotracer for PET-based molecular imaging studies. J Medicinal Chem. 2006;49:1466-1474.
62. Nishimura M: Application of three-dimensional airway algorithms in a clinical study. Proc Am Thorac Soc. 2008;5: 910-914.
63. Dolovich MB: 18F-Fluorodeoxyglucose positron emis-sion tomographic imaging of pulmonary functions, pa-thology, and drug delivery. Proc Am Thorac Soc. 2009;6: 477-485.
64. Sanchez-Crespo A, Andreo P, Larsson SA: Positron flight in human tissues and its influence on PET image spatial res-olution. Eur J Nucl Med Mol Imaging 2004;31:44-51.
65. Bailey DL, Karp JS, Surti S: Physics and instrumentation in PET. In: PE Valk, DL Bailey, DW Townsend, and MN Maisey (eds). Positron Emission Tomography: Basic Science & Clinical Practice, Chap 2. Springer-Verlag, London; pp. 41-68, 2003.
66. Chen DL, Ferkol TW, Mintun MA, Pittman JE, Rosenbluth DB, and Schuster DP: Quantifying pulmonary inflamma-tion in cystic fibrosis with positron emission tomography. Am J Respir Crit Care Med. 2006;173:1363-1369.
67. Henderson JA, Alexander BC, and Smith JJ: The food and drug administration and molecular imaging agents: po-tential challenges and opportunities. J Am Coll Radiol. 2005;2:833-840.
68. Newman SP, Pavia D, Garland N, and Clarke SW: Effects of various inhalation modes on the deposition of radioac-tive pressurized aerosols. Eur J Respir Dis. 1982;63(Suppl 119):57-65.
69. Foster W: Editorial. Is 24 hour lung retention an index of alveolar deposition. J Aerosol Med. 1988:1:1-10.
70. Heyder J, Gebhart J, Stahlhofen W, and Stuck B: Biological variability of particle deposition in the human respiratory tract during controlled and spontaneous breathing. Ann Occup Hyg. 1982;26:137-147.
71. 99mTc radi-olabeled aerosol particles targeted to central human airways using planar gamma camera imaging. J Aerosol Med Pulm Drug Deliv. 2009;22:45-54.
72. Borgström L, Olsson B, and Thorsson L: Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473-483.
73. Clark A, Chambers C, Muir D, Newhouse M, Paboojan S, and Schuler C: The effect of biphasic inhalation profiles on the deposition and clearance of coarse (6.5 mm) bolus aerosols. J Aerosol Med. 2007;20:75-82.
74. Agnew J, and Hasani A: Deposition-dependent normal ranges for radioaerosol assessment of lung mucus clear-ance. J Aerosol Med Pulm Drug Deliv. 2008;21:371-380.
75. Newman SP, Hirst PH, Pitcairn GR, and Clark AR: Un-derstanding regional lung deposition data in gamma scin-tigraphy. In: RN Dalby, PR Byron, and SJ Farr (eds). Respiratory Drug Delivery VI. Interpharm Press, Buffalo Grove, IL; pp. 9-15, 1998.
76. Newman SP, Wilding IR, and Hirst PH: Human lung de-position data: the bridge between in vitro and clinical evaluations for inhaled drug products. Int J Pharm. 2000; 208:49-60.
77. Gerrity TR: Aerosol deposition using new radioaerosol imaging techniques. In: P Byron, RN Dalby, and SJ Farr (eds). Respiratory Drug Delivery IV. Interpharm Press, Buf-falo Grove, IL; pp. 179-186, 1994.
78. Smaldone GC: Deposition patterns of nebulized drugs: is the pattern important. J Aerosol Med. 1994;7(Suppl 1): S25-S32.
79. Bondesson E, Bengtsson T, Borgström L, Nilsson L-E, Norrgren K, Trofast E, and Wollmer P: Planar gamma scintigraphy\points to consider when quantifying pul-monary dry powder aerosol deposition. Int J Pharm. 2003;258:227-240.
80. Dolovich M, and Smaldone G: Standards for in-vitro/in-vivo measurements of MDI characteristics. J Aerosol Med. 1993;6:103.
81. Gonda I: Scintigraphic techniques for measuring in vivo deposition. J Aerosol Med. 1996;9:S59-S67.
82. Chrystyn H: Pharmacokinetic methods to determine the lung deposition of nebulized drugs. Eur Respir Rev. 2000; 10:228-231.
83. Derendorf H, Hochhaus G, and Möllman H: Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med. 2001;14(Suppl 1):S9-S17.
84. Borgström L, and Nilsson M: A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res. 1990;7:1068-1070.
85. Hindle M, and Chrystyn C: Determination of the relative bioavailability of salbutamol to the lung following inhala-tion. Br J Clin Pharmacol. 1992;34:311-315.
86. Howarth PH: Why particle size should affect clinical re-sponse to inhaled therapy. J Aerosol Med. 2001;14(Suppl 1): S27-S34.
87. Schmekel B, Borgstrom L, and Wollmer P: Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. Thorax. 1991;46:225-228.
88. Edsbäcker S, Wollmer P, Selroos O, Borgstrom L, and Olsson B: Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther. 2008;21:247-258.
89. Martin AR, Thompson RB, and Finlay WH: MRI mea-surement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide particles. J Aerosol Med Pulm Drug Deliv. 2008;21:335-342
90. Code of Federal Regulations. Adulterated drugs and de-vices. Title 21, Chapter 9, Section 351, 2009
91. Code of Federal Regulations. Classification of devices in-tended for human use. Title 21, Chapter 9, Section 360c, 2009
92. Code of Federal Regulations. Types of evidence to establish bioavailability or bioequivalence. Title 21, Chapter 1, Sec-tion 320.24, 2009.
93. European Medicines Agency. Guideline on the require-ments for clinical documentation for orally inhaled prod-ucts (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. Doc Ref CPMP/EWP/4151/00, 2009.
94. Amidon GL, Lennernas H, Shah VP, and Crison JRA: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
95. Wanner A, Salathe M, and O'Riordan TG: Mucociliary clearance in the airways\state of the art. Am J Respir Crit Care Med. 1996;154:1868-1902.
96. Donaldson SH, Corcoran TE, Laube BL, and Bennett WD: Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc. 2007;4:399-405.
97. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Geary CA, Boucher RC, and Knowles MR: Effect of uridine 5-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Resp Crit Care Med. 1996;153: 1796-1801.
98. Bennett WD, Chapman WF, and Mascarella JM: The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD. Chest. 1993;103:488-495.
99. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, and Boucher RC: Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241-250.
100. Roth C, Scheuch G, and Stahlhofen W: Clearance mea-surements with radioactively labelled ultrafine particles. Ann occup Hyg. 1994;38:101-106.
101. Moeller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P, Haeussinger K, and Kreyling WG: Deposition, retention and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med. 2008;177:426-432.
102. Yang W, Peters JI, and Williams RO: Inhaled nano-particles\a current review. Int J Pharm. 2008;356:239-247.
103. Shrewsbury SB, Bosco AP, and Uster PS: Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharm. 2009;365:12-17.
104. Nyambura BK, Kellaway IW, and Taylor KM: Insulin na-noparticles: stability and aerosolization from pressurized metered dose inhalers. Int J Pharm. 2009;375:114-122.
105. Klinger C, Müller BW, and Steckel H: Insulin micro-and nanoparticles for pulmonary delivery. Int J Pharm. 2009; 377:173-179.
106. Maynard AD, Aitken RJ, Butz T, Colvin V, Donaldson K, Oberdorster G., Philbert MA, Ryan J, Seaton A, Stone V, Tinkle SS, Tran L, Walker NJ, and Warheit DB: Safe han-dling of nanotechnology. Nature. 2006;444:267-269.
107. Nel A, Xia T, Madler L, and Li N: Toxic potential of ma-terials at the nanolevel. Science. 2006;311:622-627.
108. Oberdorster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D Olin S, Monteiro-Riviere N, Warheit D, and Yang H: Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol. 2005;2:8.
109. Stoeger T, Reinhard C, Takenaka S, Schroeppel A, Karg E., Ritter B, Heyder J, and Schulz H: Instillation of six different ultrafine carbon particles indicates a surface area threshold dose for acute lung inflammation in mice. Environ Health Perspect. 2006;114:328-333.
110. Geiser M, Rothen-Rutishauser B, Kapp N, Schürch S, Kreyling W, Schulz H, Semmler M, Im Hof V, Heyder J, and Gehr P: Ultrafine particles cross cellular membranes by non-phagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect. 2005;113:1555-1560.
111. Mühlfeld C, Geiser M, Kapp N, Gehr P. and Rothen-Ru-tishauser B: Re-evaluation of pulmonary titanium dioxide nanoparticle distribution using the "relative deposition in-dex": Evidence for clearance through microvasculature. Part Fibre Toxicol. 2007;4:7.
112. Kreyling W, Semmler-Behnke M, Seitz J, Scymczak W, Wenk A, Mayer P, Takenaka S., and Obeerdörster G: Size dependence of the translocation of inhaled iridium and carbon nanoparticle aggregates from the lung of rats to the blood and secondary target organs. Inhal Toxicol. 2009;21(Suppl 1):55-60.
113. Vinzents PS, Moller P, Sorensen M, Knudsen LE, Hertel O, Jensen FP, Schibye B, and Loft S: Personal exposure to ul-trafine particles and oxidative DNA damage. Environ Health Perspect. 2005;113:1485-1490.
114. Borm P, Klaessig FC, Landry TD, Moudgil B, Pauluhn J, Thomas K, Trottier R, and Wood S: Research strategies for safety evaluation of nanomaterials, Part V: Role of disso-lution in biological fate and effects of nanoscale particles. Toxicol Sci. 2006;90:23-32.
115. Unfried K, Albrecht C, Klotz LO, von Mikecz A, Grether-Beck S, and Schins RP: Cellular responses to nano-particles: Target structures and mechanisms. Nanotoxicol. 2007;1:1-20.
116. 10). Free Radical Biol Med. 2003;34:1369-1382.
117. Rothen-Rutishauser B, Schürch S, and Gehr P: Interaction of particles with membranes. In: K Donaldson, and P Borm (eds). The Toxicology of Particles. Taylor & Francis Group, CRC Press, Boca Raton, FL; pp. 139-160, 2007.
118. Poland CA, Duffin R, Kiloch I, Maynard A, Wallace WA, Seaton A, Stone V, Brown, S, MacNee W, and Donaldson K: Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol. 2008;3:423-428.
119. Ehtezazi T, Horsfield MA, Barry PW, and O'Callaghan C: Dynamic change of the upper airway during inhalation via aerosol devices. J Aerosol Med. 2004;17:325-334.
120. Thomas B, Brightling C, Chilvers M, Rutman A, Hirst R, and O'Callaghan C: Ciliated respiratory epithelium in adults with severe asthma. Abstr Am Thoracic Soc Meet. 2008.
121. Thomas B, Wardlaw AJ, Rutman A, Hirst R, Haldar P, Brightling C, and O'Callaghan C: Ciliary function and ep-ithelial ultrastructure in mild and moderate asthma. Abstr Am Thoracic Soc Meet. 2009.
122. Gehr P, Bachofen M, and Weibel ER: The normal human lung: ultrastructure and morphometric estimation of dif-fusion capacity. Respir Physiol. 1978;32:121-140.
123. Wong JY, Rutman A, and O'Callaghan C: Recovery of the ciliated epithelium following acute bronchiolitis in infancy. Thorax. 2005;60:582-587.